Biotech/ Pharma OTCBB Stocks; OTCVolumeLeaders.com; Most Active ($0.14-$0.25 … – InvestorIdeas.com (press release)Filed Under: Graft Versus Host Disease, cadaver
Biotech/ Pharma OTCBB Stocks; OTCVolumeLeaders.com; Most Active ($0.14-$0.25 ... InvestorIdeas.com (press release) orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, ... |
- Read More
- 4 Aug 2010 4:52 PM
- Comments (0)

